Cargando…

Intracoronary Eptifibatide During Primary Percutaneous Coronary Intervention in Early Versus Late Presenters with ST Segment Elevation Myocardial Infarction: A Randomized Trial

INTRODUCTION: The role of intracoronary (IC) eptifibatide in primary percutaneous coronary intervention (PPCI) for ST segment elevation myocardial infarction (STEMI) and whether time of patient presentation affects this role are unclear. We sought to evaluate the benefit of IC eptifibatide use durin...

Descripción completa

Detalles Bibliográficos
Autores principales: Elbadawi, Ayman, Gasioch, Gerald, Elgendy, Islam Y., Mahmoud, Ahmed N., Ha, Le Dung, Ashry, Haitham Al, Shahin, Hend, Hamza, Mohamed A., Abuzaid, Ahmed S., Saad, Marwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125115/
https://www.ncbi.nlm.nih.gov/pubmed/27844422
http://dx.doi.org/10.1007/s40119-016-0073-3
_version_ 1782469933199785984
author Elbadawi, Ayman
Gasioch, Gerald
Elgendy, Islam Y.
Mahmoud, Ahmed N.
Ha, Le Dung
Ashry, Haitham Al
Shahin, Hend
Hamza, Mohamed A.
Abuzaid, Ahmed S.
Saad, Marwan
author_facet Elbadawi, Ayman
Gasioch, Gerald
Elgendy, Islam Y.
Mahmoud, Ahmed N.
Ha, Le Dung
Ashry, Haitham Al
Shahin, Hend
Hamza, Mohamed A.
Abuzaid, Ahmed S.
Saad, Marwan
author_sort Elbadawi, Ayman
collection PubMed
description INTRODUCTION: The role of intracoronary (IC) eptifibatide in primary percutaneous coronary intervention (PPCI) for ST segment elevation myocardial infarction (STEMI) and whether time of patient presentation affects this role are unclear. We sought to evaluate the benefit of IC eptifibatide use during primary PCI in early STEMI presenters compared to late STEMI presenters. METHODS: We included 70 patients who presented with STEMI and were eligible for PPCI. On the basis of symptom-to-door time, patients were classified into two arms: early (<3 h, n = 34) vs late (≥3 h, n = 36) presenters. They were then randomized to local IC eptifibatide infusion vs standard care (control group). The primary end point was post-PCI myocardial blush grade (MBG) in the culprit vessel. Other end points included corrected TIMI frame count (cTFC), ST segment resolution (STR) ≥70%, and peak CKMB. RESULTS: In the early presenters arm, no difference was observed in MBG results ≥2 in the IC eptifibatide and control groups (100% vs 82%; p = 0.23). In the late presenters arm, the eptifibatide subgroup was associated with improved MBG ≥2 (100% vs 50%; p = 0.001). IC eptifibatide in both early and late presenters was associated with less cTFC (early presenters 19 vs. 25.6, p = 0.001; late presenters 20 vs. 31.5, p < 0.001) and less peak CKMB (early presenters 210 vs 260 IU/L, p = 0.006; late presenters 228 vs 318 IU/L, p = 0.005) compared with the control group. No difference existed between both groups in STR index in early and late presenters. CONCLUSION: IC eptifibatide might improve the reperfusion markers during PPCI for STEMI patients presenting after 3 h from onset of symptoms. A large randomized study is recommended to ascertain the benefits of IC eptifibatide in late presenters on clinical outcomes.
format Online
Article
Text
id pubmed-5125115
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-51251152016-12-12 Intracoronary Eptifibatide During Primary Percutaneous Coronary Intervention in Early Versus Late Presenters with ST Segment Elevation Myocardial Infarction: A Randomized Trial Elbadawi, Ayman Gasioch, Gerald Elgendy, Islam Y. Mahmoud, Ahmed N. Ha, Le Dung Ashry, Haitham Al Shahin, Hend Hamza, Mohamed A. Abuzaid, Ahmed S. Saad, Marwan Cardiol Ther Original Research INTRODUCTION: The role of intracoronary (IC) eptifibatide in primary percutaneous coronary intervention (PPCI) for ST segment elevation myocardial infarction (STEMI) and whether time of patient presentation affects this role are unclear. We sought to evaluate the benefit of IC eptifibatide use during primary PCI in early STEMI presenters compared to late STEMI presenters. METHODS: We included 70 patients who presented with STEMI and were eligible for PPCI. On the basis of symptom-to-door time, patients were classified into two arms: early (<3 h, n = 34) vs late (≥3 h, n = 36) presenters. They were then randomized to local IC eptifibatide infusion vs standard care (control group). The primary end point was post-PCI myocardial blush grade (MBG) in the culprit vessel. Other end points included corrected TIMI frame count (cTFC), ST segment resolution (STR) ≥70%, and peak CKMB. RESULTS: In the early presenters arm, no difference was observed in MBG results ≥2 in the IC eptifibatide and control groups (100% vs 82%; p = 0.23). In the late presenters arm, the eptifibatide subgroup was associated with improved MBG ≥2 (100% vs 50%; p = 0.001). IC eptifibatide in both early and late presenters was associated with less cTFC (early presenters 19 vs. 25.6, p = 0.001; late presenters 20 vs. 31.5, p < 0.001) and less peak CKMB (early presenters 210 vs 260 IU/L, p = 0.006; late presenters 228 vs 318 IU/L, p = 0.005) compared with the control group. No difference existed between both groups in STR index in early and late presenters. CONCLUSION: IC eptifibatide might improve the reperfusion markers during PPCI for STEMI patients presenting after 3 h from onset of symptoms. A large randomized study is recommended to ascertain the benefits of IC eptifibatide in late presenters on clinical outcomes. Springer Healthcare 2016-11-14 2016-12 /pmc/articles/PMC5125115/ /pubmed/27844422 http://dx.doi.org/10.1007/s40119-016-0073-3 Text en © The Author(s) 2016 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Elbadawi, Ayman
Gasioch, Gerald
Elgendy, Islam Y.
Mahmoud, Ahmed N.
Ha, Le Dung
Ashry, Haitham Al
Shahin, Hend
Hamza, Mohamed A.
Abuzaid, Ahmed S.
Saad, Marwan
Intracoronary Eptifibatide During Primary Percutaneous Coronary Intervention in Early Versus Late Presenters with ST Segment Elevation Myocardial Infarction: A Randomized Trial
title Intracoronary Eptifibatide During Primary Percutaneous Coronary Intervention in Early Versus Late Presenters with ST Segment Elevation Myocardial Infarction: A Randomized Trial
title_full Intracoronary Eptifibatide During Primary Percutaneous Coronary Intervention in Early Versus Late Presenters with ST Segment Elevation Myocardial Infarction: A Randomized Trial
title_fullStr Intracoronary Eptifibatide During Primary Percutaneous Coronary Intervention in Early Versus Late Presenters with ST Segment Elevation Myocardial Infarction: A Randomized Trial
title_full_unstemmed Intracoronary Eptifibatide During Primary Percutaneous Coronary Intervention in Early Versus Late Presenters with ST Segment Elevation Myocardial Infarction: A Randomized Trial
title_short Intracoronary Eptifibatide During Primary Percutaneous Coronary Intervention in Early Versus Late Presenters with ST Segment Elevation Myocardial Infarction: A Randomized Trial
title_sort intracoronary eptifibatide during primary percutaneous coronary intervention in early versus late presenters with st segment elevation myocardial infarction: a randomized trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125115/
https://www.ncbi.nlm.nih.gov/pubmed/27844422
http://dx.doi.org/10.1007/s40119-016-0073-3
work_keys_str_mv AT elbadawiayman intracoronaryeptifibatideduringprimarypercutaneouscoronaryinterventioninearlyversuslatepresenterswithstsegmentelevationmyocardialinfarctionarandomizedtrial
AT gasiochgerald intracoronaryeptifibatideduringprimarypercutaneouscoronaryinterventioninearlyversuslatepresenterswithstsegmentelevationmyocardialinfarctionarandomizedtrial
AT elgendyislamy intracoronaryeptifibatideduringprimarypercutaneouscoronaryinterventioninearlyversuslatepresenterswithstsegmentelevationmyocardialinfarctionarandomizedtrial
AT mahmoudahmedn intracoronaryeptifibatideduringprimarypercutaneouscoronaryinterventioninearlyversuslatepresenterswithstsegmentelevationmyocardialinfarctionarandomizedtrial
AT haledung intracoronaryeptifibatideduringprimarypercutaneouscoronaryinterventioninearlyversuslatepresenterswithstsegmentelevationmyocardialinfarctionarandomizedtrial
AT ashryhaithamal intracoronaryeptifibatideduringprimarypercutaneouscoronaryinterventioninearlyversuslatepresenterswithstsegmentelevationmyocardialinfarctionarandomizedtrial
AT shahinhend intracoronaryeptifibatideduringprimarypercutaneouscoronaryinterventioninearlyversuslatepresenterswithstsegmentelevationmyocardialinfarctionarandomizedtrial
AT hamzamohameda intracoronaryeptifibatideduringprimarypercutaneouscoronaryinterventioninearlyversuslatepresenterswithstsegmentelevationmyocardialinfarctionarandomizedtrial
AT abuzaidahmeds intracoronaryeptifibatideduringprimarypercutaneouscoronaryinterventioninearlyversuslatepresenterswithstsegmentelevationmyocardialinfarctionarandomizedtrial
AT saadmarwan intracoronaryeptifibatideduringprimarypercutaneouscoronaryinterventioninearlyversuslatepresenterswithstsegmentelevationmyocardialinfarctionarandomizedtrial